Inhibitex, Inc. (NASDAQ: INHX)

Inhibitex, Inc. (NASDAQ: INHX) is a biopharmaceutical company engaging in the development of differentiated anti-infective products designed to prevent and treat serious infections. The company’s products include FV-100, a nucleoside analogue prodrug; HIV Integrase Inhibitors class of anti-retroviral agents; and a series of nucleoside and non-nucleoside HCV polymerase inhibitors designed to treat the hepatitis C virus. For further information, visit the Company’s web site at www.inhibitex.com.